Product Code: PMRREP33046
Oncology Mice Models Market - Scope of Report
The latest publication by Persistence Market Research on the oncology mice models market evaluates the opportunities and current market landscape and provides detailed analysis and updates about corresponding sections affecting the market. The study offers detailed insights on current market dynamics, which include the drivers, restraints, trends, and opportunities in the market. The principal aim of the market study is to present exclusive information about how the market will perform during the forecast period of 2022-2032.
Important indicators for the successful growth of the market are presented in this comprehensive report, which includes a Year-on-Year (Y-o-Y) growth analysis of the market, and compounded annual growth rate (CAGR), which are described exhaustively in Persistence Market Research's study. This research study can support readers to know the demand for oncology mice models and the quantitative development opportunities during the study period.
The research is beneficial for shareholders in the landscape, including investors, manufacturers, service providers, distributors, and suppliers, and can help them in developing suitable business strategies to flourish in the oncology mice models market. The insights and information presented in this Persistence Market Research study can be leveraged by shareholders in the oncology mice models market, industry experts, investors, researchers, and reporters, as well as business enthusiasts.
Market statistics, as well as information linked to the macro- as well as micro-economic variables affecting the business scenario in the oncology mice models market are also included in the current study. Depending on potential developments in the market, substantive insights are also encountered in this report. Additionally, by the data submitted in this report, minor companies and new entrants in the industry can be aided in making suitable company choices to achieve traction in the market.
Key Market Segments
Persistence Market Research's study on the oncology mice models market offers information divided into three important segments - product, end user, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.
Product
Humanized Immune System Mice Models
Syngeneic Tumor Mice Models
Immunodeficient Mice Models
NOG Mice Models
Spontaneous Tumor Mice Models
Others
End User
Contract Research Organizations
Pharma and Biopharma Companies
Academic and Research Institutes
Region
North America
Latin America
Europe
Asia Pacific
Middle East and Africa (MEA)
Key Questions Answered in Report
Which regions will continue to remain the most profitable markets for oncology mice models over the coming years?
How will changing trends impact the market?
How has the COVID-19 crisis impacted market growth?
How can market players capture the low-hanging opportunities in developed regions?
What are the strategies of stakeholders in the market to shape their position in this landscape?
What are the restraining factors that investors need to be aware of and might tackle while investing in the market?
What are the developmental trends that will impact the market?
How can companies in the oncology mice models market avail themselves the growth opportunities in developed and emerging sectors?
Research Methodology
In Persistence Market Research's study, a unique research methodology is utilized to conduct extensive research on the growth of the oncology mice models market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure the accuracy and reliability of the conclusions.
Secondary resources referred to by analysts during the production of the market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.
Comprehensive information acquired from primary and secondary resources acts as validation from companies in the market and makes Persistence Market Research's projections on the growth prospects of the oncology mice models market more accurate and reliable
Table of Contents
1. Executive Summary
- 1.1. Global Market Outlook
- 1.2. Demand Side Trends
- 1.3. Supply Side Trends
- 1.4. Analysis and Recommendations
2. Market Overview
- 2.1. Market Coverage / Taxonomy
- 2.2. Market Definition / Scope / Limitations
- 2.3. Inclusions & Exclusions
3. Key Market Trends
- 3.1. Key Trends Impacting the Market
- 3.2. Product Innovation / Development Trends
4. Key Success Factors
- 4.1. Oncology Drugs - Pipeline Analysis
- 4.1.1. By Intervention
- 4.1.2. By Phase
- 4.1.3. By Funding Authority
- 4.2. Immuno-Oncology Drugs - Pipeline Analysis
- 4.2.1. By Phase
- 4.2.2. By Funding Authority
- 4.3. List of Pharma Companies That Have Ongoing Immuno-Oncology Clinical Trials
- 4.4. List of Academic & Research Institutes Involved In Ongoing Immuno-Oncology Clinical Trials
- 4.5. List of Preclinical CROs
- 4.6. Parent Market Analysis
- 4.7. Relative Number of Combination Oncology Therapy Trials
- 4.8. Landscape of Immuno-Oncology Drug Development
- 4.9. List of Preclinical immuno-oncology models
- 4.9.1. Cell lines
- 4.9.2. Mice Models
- 4.9.3. Organoids/ spheroids
- 4.10. Key Regulatory Scenario
- 4.11. Porter's Analysis
- 4.12. PESTLE Analysis
- 4.13. Supply Chain Analysis
5. Market Background
- 5.1. Macro-Economic Factors
- 5.1.1. Global GDP Growth Outlook
- 5.1.2. Global Healthcare Expenditure
- 5.2. Forecast Factors - Relevance & Impact
- 5.2.1. Covid-19 Pandemic
- 5.2.2. Prevalence of cancer
- 5.2.3. Rise in R&D investments
- 5.2.4. Stringent Regulations
- 5.2.5. Rise in number of pre-clinical and clinical studies
- 5.2.6. Increasing investment in Cancer research
- 5.2.7. GDP Growth
- 5.2.8. Advancements in Models
- 5.3. Market Dynamics
- 5.3.1. Drivers
- 5.3.2. Restraints
- 5.3.3. Opportunity Analysis
6. COVID19 Crisis Analysis
- 6.1. Current COVID19 Statistics and Probable Future Impact
- 6.2. Current GDP Projection and Probable Impact
- 6.3. Current Economic Projection as compared to 2008 Economic analysis
- 6.4. COVID19 and Impact Analysis
- 6.5. Recovery Scenario - Short term, Midterm, and Long Term Impact
7. Global Oncology Mice Models Market Demand (in Value or Size in US$ Mn) Analysis 2017-2021 and Forecast, 2022-2032
- 7.1. Historical Market Value (US$ Mn) Analysis, 2017- 2021
- 7.2. Current and Future Market Value (US$ Mn) Projections, 2022-2032
- 7.2.1. Y-o-Y Growth Trend Analysis
- 7.2.2. Absolute $ Opportunity Analysis
8. Global Oncology Mice Models Market Analysis 2017-2021 and Forecast 2022-2032, by Product
- 8.1. Introduction / Key Findings
- 8.2. Historical Market Size (US$ Mn) Analysis By Product, 2017-2021
- 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product, 2022-2032
- 8.3.1. Humanized Immune System Mice Models
- 8.3.2. Syngeneic Tumor Mice Models
- 8.3.3. Immunodeficient Mice Models
- 8.3.4. NOG Mice Models
- 8.3.5. Spontaneous Tumor Mice Models
- 8.3.6. Others
- 8.4. Market Attractiveness Analysis By Product
9. Global Oncology Mice Models Market Analysis 2017-2021 and Forecast 2022-2032, by End User
- 9.1. Introduction / Key Findings
- 9.2. Historical Market Size (US$ Mn) Analysis By End User, 2017-2021
- 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2022-2032
- 9.3.1. Contract Research Organizations
- 9.3.2. Pharma and Biopharma Companies
- 9.3.3. Academic and Research Institutes
- 9.4. Market Attractiveness Analysis By Indication
10. Global Oncology Mice Models Market Analysis 2017-2021 and Forecast 2022-2032, by Region
- 10.1. Introduction / Key Findings
- 10.2. Historical Market Size (US$ Mn) Analysis By Region, 2017-2021
- 10.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2022-2032
- 10.3.1. The North America
- 10.3.2. Latin America
- 10.3.3. Europe
- 10.3.4. Asia Pacific
- 10.3.5. Middle East and Africa (MEA)
- 10.4 Market Attractiveness Analysis
11. North America Oncology Mice Models Market Analysis 2017-2021 and Forecast 2022-2032
- 11.1. Introduction / Key Findings
- 11.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021
- 11.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032
- 11.3.1. By Country
- 11.3.2. By Product
- 11.3.3. By End User
- 11.4. Market Attractiveness Analysis
- 11.5. Key Market Participants - Intensity Mapping
- 11.6. Drivers and Restraints - Impact Analysis
12. Latin America Oncology Mice Models Market Analysis 2017-2021 and Forecast 2022-2032
- 12.1. Introduction / Key Findings
- 12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021
- 12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032
- 12.3.1. By Country
- 12.3.2. By Product
- 12.3.3. By End User
- 12.4. Market Attractiveness Analysis
- 12.5. Key Market Participants - Intensity Mapping
- 12.6. Drivers and Restraints - Impact Analysis
13. Europe Oncology Mice Models Market Analysis 2017-2021 and Forecast 2022-2032
- 13.1. Introduction / Key Findings
- 13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021
- 13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032
- 13.3.1. By Country
- 13.3.2. By Product
- 13.3.3. By End User
- 13.4. Market Attractiveness Analysis
- 13.5. Key Market Participants - Intensity Mapping
- 13.6. Drivers and Restraints - Impact Analysis
14. Asia Pacific Oncology Mice Models Market Analysis 2017-2021 and Forecast 2022-2032
- 14.1. Introduction / Key Findings
- 14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021
- 14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032
- 14.3.1. By Country
- 14.3.2. By Product
- 14.3.3. By End User
- 14.4. Market Attractiveness Analysis
- 14.5. Key Market Participants - Intensity Mapping
- 14.6. Drivers and Restraints - Impact Analysis
15. Middle East and Africa (MEA) Oncology Mice Models Market Analysis 2017-2021 and Forecast 2022-2032
- 15.1. Introduction / Key Findings
- 15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021
- 15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032
- 15.3.1. By Country
- 15.3.2. By Product
- 15.3.3. By End User
- 15.4. Market Attractiveness Analysis
- 15.5. Key Market Participants - Intensity Mapping
- 15.6. Drivers and Restraints - Impact Analysis
16. Country Level Medical Cart Market Analysis and Forecast 2022 & 2032
- 16.1. Introduction
- 16.1.1. Market Value Proportion Analysis
- 16.1.2. Global VS. Country Growth Comparison
- 16.2. U.S. Medical Cart Market Analysis
- 16.2.1. By Product
- 16.2.2. By End User
- 16.3. Canada Medical Cart Market Analysis
- 16.3.1. By Product
- 16.3.2. By End User
- 16.4. Brazil Medical Cart Market Analysis
- 16.4.1. By Product
- 16.4.2. By End User
- 16.5. Argentina Medical Cart Market Analysis
- 16.5.1. By Product
- 16.5.2. By End User
- 16.6. Mexico Medical Cart Market Analysis
- 16.6.1. By Product
- 16.6.2. By End User
- 16.7. Germany Medical Cart Market Analysis
- 16.7.1. By Product
- 16.7.2. By End User
- 16.8. Italy Medical Cart Market Analysis
- 16.8.1. By Product
- 16.8.2. By End User
- 16.9. France Medical Cart Market Analysis
- 16.9.1. By Product
- 16.9.2. By End User
- 16.10. U.K. Medical Cart Market Analysis
- 16.10.1. By Product
- 16.10.2. By End User
- 16.11. Spain Medical Cart Market Analysis
- 16.11.1. By Product
- 16.11.2. By End User
- 16.12. BENELUX Medical Cart Market Analysis
- 16.12.1. By Product
- 16.12.2. By End User
- 16.13. Russia Medical Cart Market Analysis
- 16.13.1. By Product
- 16.13.2. By End User
- 16.14. China Medical Cart Market Analysis
- 16.14.1. By Product
- 16.14.2. By End User
- 16.15. Japan Medical Cart Market Analysis
- 16.15.1. By Product
- 16.15.2. By End User
- 16.16. India Medical Cart Market Analysis
- 16.16.1. By Product
- 16.16.2. By End User
- 16.17. Australia and New Zealand Medical Cart Market Analysis
- 16.17.1. By Product
- 16.17.2. By End User
- 16.18. GCC Countries Medical Cart Market Analysis
- 16.18.1. By Product
- 16.18.2. By End User
- 16.19. South Africa Medical Cart Market Analysis
- 16.19.1. By Product
- 16.19.2. By End User
17. Market Structure Analysis
- 17.1. Market Analysis by Tier of Companies
- 17.2. Market Share Analysis of Top Players
18. Competition Analysis
- 18.1. Competition Benchmarking
- 18.2. Competition Dashboard
- 18.3. Competition Deep Dive
- 18.3.1. The Jackson Laboratory
- 18.3.1.1. Overview
- 18.3.1.2. Product Portfolio
- 18.3.1.3. Key Financials
- 18.3.1.4. SWOT Analysis
- 18.3.1.5. Sales Footprint
- 18.3.1.6. Strategy Overview
- 18.3.1.6.1. Marketing Strategy
- 18.3.1.6.2. Product Strategy
- 18.3.1.6.3. Channel Strategy
- 18.3.2. Taconic Biosciences
- 18.3.2.1. Overview
- 18.3.2.2. Product Portfolio
- 18.3.2.3. Key Financials
- 18.3.2.4. SWOT Analysis
- 18.3.2.5. Sales Footprint
- 18.3.2.6. Strategy Overview
- 18.3.2.6.1. Marketing Strategy
- 18.3.2.6.2. Product Strategy
- 18.3.2.6.3. Channel Strategy
- 18.3.3. Charles River Laboratories
- 18.3.3.1. Overview
- 18.3.3.2. Product Portfolio
- 18.3.3.3. Key Financials
- 18.3.3.4. SWOT Analysis
- 18.3.3.5. Sales Footprint
- 18.3.3.6. Strategy Overview
- 18.3.3.6.1. Marketing Strategy
- 18.3.3.6.2. Product Strategy
- 18.3.3.6.3. Channel Strategy
- 18.3.4. Shanghai Model Organisms Center Inc.
- 18.3.4.1. Overview
- 18.3.4.2. Product Portfolio
- 18.3.4.3. Key Financials
- 18.3.4.4. SWOT Analysis
- 18.3.4.5. Sales Footprint
- 18.3.4.6. Strategy Overview
- 18.3.4.6.1. Marketing Strategy
- 18.3.4.6.2. Product Strategy
- 18.3.4.6.3. Channel Strategy
- 18.3.5. Envigo
- 18.3.5.1. Overview
- 18.3.5.2. Product Portfolio
- 18.3.5.3. Key Financials
- 18.3.5.4. SWOT Analysis
- 18.3.5.5. Sales Footprint
- 18.3.5.6. Strategy Overview
- 18.3.5.6.1. Marketing Strategy
- 18.3.5.6.2. Product Strategy
- 18.3.5.6.3. Channel Strategy
- 18.3.6. Biocytogen
- 18.3.6.1. Overview
- 18.3.6.2. Product Portfolio
- 18.3.6.3. Key Financials
- 18.3.6.4. SWOT Analysis
- 18.3.6.5. Sales Footprint
- 18.3.6.6. Strategy Overview
- 18.3.6.6.1. Marketing Strategy
- 18.3.6.6.2. Product Strategy
- 18.3.6.6.3. Channel Strategy
- 18.3.7. Genoway
- 18.3.7.1. Overview
- 18.3.7.2. Product Portfolio
- 18.3.7.3. Key Financials
- 18.3.7.4. SWOT Analysis
- 18.3.7.5. Sales Footprint
- 18.3.7.6. Strategy Overview
- 18.3.7.6.1. Marketing Strategy
- 18.3.7.6.2. Product Strategy
- 18.3.7.6.3. Channel Strategy
- 18.3.8. Crown Bioscience Inc. (JSR Corporation).
- 18.3.8.1. Overview
- 18.3.8.2. Product Portfolio
- 18.3.8.3. Key Financials
- 18.3.8.4. SWOT Analysis
- 18.3.8.5. Sales Footprint
- 18.3.8.6. Strategy Overview
- 18.3.8.6.1. Marketing Strategy
- 18.3.8.6.2. Product Strategy
- 18.3.8.6.3. Channel Strategy
- 18.3.9. Cyagen
- 18.3.9.1. Overview
- 18.3.9.2. Product Portfolio
- 18.3.9.3. Key Financials
- 18.3.9.4. SWOT Analysis
- 18.3.9.5. Sales Footprint
- 18.3.9.6. Strategy Overview
- 18.3.9.6.1. Marketing Strategy
- 18.3.9.6.2. Product Strategy
- 18.3.9.6.3. Channel Strategy
- 18.3.10. Applied stem cells
- 18.3.10.1. Overview
- 18.3.10.2. Product Portfolio
- 18.3.10.3. Key Financials
- 18.3.10.4. SWOT Analysis
- 18.3.10.5. Sales Footprint
- 18.3.10.6. Strategy Overview
- 18.3.10.6.1. Marketing Strategy
- 18.3.10.6.2. Product Strategy
- 18.3.10.6.3. Channel Strategy
- 18.3.11. Ingenious Targeting Laboratory
- 18.3.11.1. Overview
- 18.3.11.2. Product Portfolio
- 18.3.11.3. Key Financials
- 18.3.11.4. SWOT Analysis
- 18.3.11.5. Sales Footprint
- 18.3.11.6. Strategy Overview
- 18.3.11.6.1. Marketing Strategy
- 18.3.11.6.2. Product Strategy
- 18.3.11.6.3. Channel Strategy
- 18.3.12. PolyGene - Transgenic mice model company
- 18.3.12.1. Overview
- 18.3.12.2. Product Portfolio
- 18.3.12.3. Key Financials
- 18.3.12.4. SWOT Analysis
- 18.3.12.5. Sales Footprint
- 18.3.12.6. Strategy Overview
- 18.3.12.6.1. Marketing Strategy
- 18.3.12.6.2. Product Strategy
- 18.3.12.6.3. Channel Strategy
- 18.3.13. Creative Biolabs
- 18.3.13.1. Overview
- 18.3.13.2. Product Portfolio
- 18.3.13.3. Key Financials
- 18.3.13.4. SWOT Analysis
- 18.3.13.5. Sales Footprint
- 18.3.13.6. Strategy Overview
- 18.3.13.6.1. Marketing Strategy
- 18.3.13.6.2. Product Strategy
- 18.3.13.6.3. Channel Strategy
- 18.3.14. TransCure Bioservices
- 18.3.14.1. Overview
- 18.3.14.2. Product Portfolio
- 18.3.14.3. Key Financials
- 18.3.14.4. SWOT Analysis
- 18.3.14.5. Sales Footprint
- 18.3.14.6. Strategy Overview
- 18.3.14.6.1. Marketing Strategy
- 18.3.14.6.2. Product Strategy
- 18.3.14.6.3. Channel Strategy
- 18.3.15. Champions Oncology Inc
- 18.3.15.1. Overview
- 18.3.15.2. Product Portfolio
- 18.3.15.3. Key Financials
- 18.3.15.4. SWOT Analysis
- 18.3.15.5. Sales Footprint
- 18.3.15.6. Strategy Overview
- 18.3.15.6.1. Marketing Strategy
- 18.3.15.6.2. Product Strategy
- 18.3.15.6.3. Channel Strategy
- 18.3.16. Certis Oncology
- 18.3.16.1. Overview
- 18.3.16.2. Product Portfolio
- 18.3.16.3. Key Financials
- 18.3.16.4. SWOT Analysis
- 18.3.16.5. Sales Footprint
- 18.3.16.6. Strategy Overview
- 18.3.16.6.1. Marketing Strategy
- 18.3.16.6.2. Product Strategy
- 18.3.16.6.3. Channel Strategy
- 18.3.17. Signature
- 18.3.17.1. Overview
- 18.3.17.2. Product Portfolio
- 18.3.17.3. Key Financials
- 18.3.17.4. SWOT Analysis
- 18.3.17.5. Sales Footprint
- 18.3.17.6. Strategy Overview
- 18.3.17.6.1. Marketing Strategy
- 18.3.17.6.2. Product Strategy
- 18.3.17.6.3. Channel Strategy
- 18.3.18. Pharmaron
- 18.3.18.1. Overview
- 18.3.18.2. Product Portfolio
- 18.3.18.3. Key Financials
- 18.3.18.4. SWOT Analysis
- 18.3.18.5. Sales Footprint
- 18.3.18.6. Strategy Overview
- 18.3.18.6.1. Marketing Strategy
- 18.3.18.6.2. Product Strategy
- 18.3.18.6.3. Channel Strategy
- 18.3.19. Laboratory Corporation of America Holdings
- 18.3.19.1. Overview
- 18.3.19.2. Product Portfolio
- 18.3.19.3. Key Financials
- 18.3.19.4. SWOT Analysis
- 18.3.19.5. Sales Footprint
- 18.3.19.6. Strategy Overview
- 18.3.19.6.1. Marketing Strategy
- 18.3.19.6.2. Product Strategy
- 18.3.19.6.3. Channel Strategy
- 18.3.20. Gempharmatech
- 18.3.20.1. Overview
- 18.3.20.2. Product Portfolio
- 18.3.20.3. Key Financials
- 18.3.20.4. SWOT Analysis
- 18.3.20.5. Sales Footprint
- 18.3.20.6. Strategy Overview
- 18.3.20.6.1. Marketing Strategy
- 18.3.20.6.2. Product Strategy
- 18.3.20.6.3. Channel Strategy
- 18.3.21. Janvier Labs
- 18.3.21.1. Overview
- 18.3.21.2. Product Portfolio
- 18.3.21.3. Key Financials
- 18.3.21.4. SWOT Analysis
- 18.3.21.5. Sales Footprint
- 18.3.21.6. Strategy Overview
- 18.3.21.6.1. Marketing Strategy
- 18.3.21.6.2. Product Strategy
- 18.3.21.6.3. Channel Strategy
- 18.3.22. Harbour BioMed
- 18.3.22.1. Overview
- 18.3.22.2. Product Portfolio
- 18.3.22.3. Key Financials
- 18.3.22.4. SWOT Analysis
- 18.3.22.5. Sales Footprint
- 18.3.22.6. Strategy Overview
- 18.3.22.6.1. Marketing Strategy
- 18.3.22.6.2. Product Strategy
- 18.3.22.6.3. Channel Strategy
19. Assumptions and Acronyms Used
20. Research Methodology